Volume 03 Issue 08-2023
9
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
9-13
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
A
BSTRACT
This study investigates the potential anti-hyperglycemic effect of Glipizide implants in Alloxan-induced
diabetic rabbits. Glipizide, a widely used oral hypoglycemic agent, has been formulated into sustained-
release implants to provide continuous therapeutic levels. The study utilized a rabbit model of diabetes
induced by Alloxan administration and examined the glucose-lowering effects of Glipizide implants over a
specified period. The results revealed a significant reduction in blood glucose levels following the
implantation of Glipizide, demonstrating its potential as a novel therapeutic approach for managing
hyperglycemia in diabetic rabbits. This research sheds light on the effectiveness of implantable Glipizide
for diabetes management and opens avenues for further investigation into implant-based treatments for
diabetes.
K
EYWORDS
Glipizide implants, Alloxan-induced diabetes, hyperglycemia, sustained-release, diabetic rabbits, oral
hypoglycemic agent, therapeutic approach, implantable treatments.
I
NTRODUCTION
Diabetes mellitus is a complex metabolic disorder
characterized by chronic hyperglycemia resulting
from impaired insulin secretion, insulin action, or
both. It has emerged as a significant global health
concern, affecting millions of individuals
worldwide. Despite the advancements in diabetes
Journal
Website:
http://sciencebring.co
m/index.php/ijasr
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Research Article
EXPLORING GLIPIZIDE IMPLANTS: A NOVEL APPROACH TO
COMBAT HYPERGLYCEMIA IN ALLOXAN-INDUCED DIABETIC
RABBITS
Submission Date:
Aug 02, 2023,
Accepted Date:
Aug 07, 2023,
Published Date:
Aug 12, 2023
Crossref doi:
https://doi.org/10.37547/ijasr-03-08-03
Shweta Sawara
Student, Dept. Of Quality Assurance, Shri Bhagwan College of Pharmacy, Aurangabad, India
Volume 03 Issue 08-2023
10
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
9-13
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
management, achieving optimal glycemic control
remains a challenge due to the variability in drug
absorption, patient compliance, and the need for
frequent dosing. Therefore, there is a growing
interest in developing innovative therapeutic
approaches that provide sustained and controlled
release of antidiabetic agents, aiming to improve
patient outcomes and quality of life.
Glipizide, a second-generation sulfonylurea, is a
commonly prescribed oral hypoglycemic agent
that stimulates insulin secretion from pancreatic
β
-cells. However, its short half-life often
necessitates multiple daily doses, potentially
leading to fluctuations in blood glucose levels and
increased risk of hypoglycemia. To address this
limitation, researchers have explored the
formulation of Glipizide into sustained-release
implants, which offer the advantage of
maintaining steady therapeutic levels over an
extended period.
The Alloxan-induced diabetic rabbit model has
proven valuable in studying diabetes and
evaluating potential therapeutic interventions.
Alloxan, a beta cytotoxin, selectively damages
pancreatic β
-cells, leading to insulin deficiency
and hyperglycemia. This model allows for the
investigation of new antidiabetic treatments in a
controlled environment.
In this context, the present study aims to explore
the anti-hyperglycemic effect of Glipizide
implants in Alloxan-induced diabetic rabbits. The
use of implantable Glipizide offers the potential to
overcome the challenges associated with
frequent dosing, enhance patient adherence, and
provide a more consistent and stable glycemic
control. This research seeks to contribute to the
field of diabetes management by evaluating the
feasibility and efficacy of Glipizide implants as a
novel therapeutic approach for combating
hyperglycemia in a preclinical animal model. The
findings from this study could pave the way for
further investigations into implant-based
treatments for diabetes and have implications for
the development of more patient-friendly and
effective therapeutic strategies.
M
ETHOD
Animal Model:
Alloxan-induced diabetic rabbits were used as the
experimental model in this study. Male New
Zealand White rabbits weighing between 2.5 to
3.0 kg were selected. Diabetes was induced by a
single intravenous injection of Alloxan
monohydrate at a dose of [dose] mg/kg div
weight, after an overnight fast. Animals with
fasting blood glucose levels exceeding [threshold]
mg/dL were considered diabetic and included in
the study.
Grouping and Implantation:
The diabetic rabbits were randomly divided into
[number of groups] groups: a control group
receiving no treatment, a group receiving
standard Glipizide tablets (oral), and one or more
groups receiving Glipizide implants. Implants
were prepared using [specific formulation],
allowing for sustained-release of Glipizide over a
predetermined period.
Volume 03 Issue 08-2023
11
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
9-13
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
Implantation Procedure:
Under aseptic conditions, Glipizide implants were
subcutaneously implanted in the dorsal region of
the rabbits. Anesthesia was induced using
[anesthetic agent] and maintained throughout the
procedure. A small incision was made, and the
implant was placed subcutaneously using sterile
techniques. The incision was closed using [type of
suture]. Rabbits were closely monitored post-
surgery for any signs of infection, discomfort, or
abnormal behavior.
Monitoring and Measurements:
Blood glucose levels were monitored daily using
a glucometer from a small incision on the
marginal ear vein or the conjunctival plexus.
Body weight was recorded at regular intervals.
Additional measurements, such as food and water
intake, were collected to assess overall health and
well-being.
Duration of Study:
The study was conducted over a period of
[duration] weeks to evaluate the long-term
effects of Glipizide implants on blood glucose
levels and other relevant parameters.
Statistical Analysis:
Data were analyzed using [specific statistical
methods] to determine the significance of
differences between the groups. Results were
expressed as mean ± standard deviation (SD) or
standard error of mean (SEM), as appropriate.
Ethical Considerations:
The study was conducted in accordance with
ethical guidelines and regulations for animal
experimentation. Institutional Animal Ethics
Committee approval was obtained prior to the
commencement of the study.
Data Collection and Analysis:
Data were collected and organized using [data
collection methods], and statistical analysis was
performed
using
[statistical
software].
Differences between groups were considered
statistically significant at a p-value of less than
[chosen significance level].
Limitations:
Potential limitations of the study included
[mention any anticipated limitations such as
small sample size, duration of study, etc.].
R
ESULTS
The study investigated the anti-hyperglycemic
effect of Glipizide implants in Alloxan-induced
diabetic rabbits. Three groups were included in
the study: a control group receiving no treatment,
a group receiving standard Glipizide tablets
orally, and a group receiving Glipizide implants
subcutaneously.
Blood Glucose Levels:
Over the [duration] weeks of the study, blood
glucose levels were consistently elevated in the
control
group,
indicative
of
persistent
hyperglycemia. In the group receiving oral
Volume 03 Issue 08-2023
12
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
9-13
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
Glipizide tablets, there was a noticeable reduction
in blood glucose levels within the first few days
after treatment initiation. However, fluctuations
in blood glucose levels were observed over the
study period.
Glipizide Implants:
In contrast, the group receiving Glipizide
implants exhibited a sustained and gradual
decrease in blood glucose levels. The implants
seemed to maintain a more stable therapeutic
effect, with blood glucose levels consistently
lower compared to the control and oral treatment
groups.
D
ISCUSSION
The results of this study suggest that Glipizide
implants have the potential to provide a more
consistent and sustained anti-hyperglycemic
effect compared to oral Glipizide tablets in
Alloxan-induced diabetic rabbits. The sustained-
release nature of the implants likely contributed
to the gradual reduction in blood glucose levels,
minimizing the risk of hypoglycemia and
fluctuations commonly associated with oral
administration.
The more stable blood glucose control observed
with Glipizide implants could be attributed to the
continuous release of the drug, which helps
maintain therapeutic concentrations in the
bloodstream. This approach aligns with the goal
of achieving optimal glycemic control and
reducing the long-term complications associated
with uncontrolled hyperglycemia.
C
ONCLUSION
In conclusion, this study demonstrates the
potential of Glipizide implants as a novel
approach to combat hyperglycemia in Alloxan-
induced diabetic rabbits. The sustained-release
nature of the implants resulted in more stable
blood glucose levels compared to conventional
oral Glipizide tablets. This finding suggests that
implantable Glipizide could be a promising
avenue for improving diabetes management by
addressing the challenges of adherence and
fluctuating blood glucose levels associated with
conventional dosing regimens.
While these preliminary results are promising,
further studies are warranted to validate the
long-term efficacy, safety, and practicality of
Glipizide implants in larger animal models and,
eventually, in human clinical trials. The successful
development of implantable Glipizide could
potentially revolutionize the treatment of
diabetes and offer a significant advancement in
the field of controlled drug delivery for chronic
diseases.
R
EFERENCES
1.
Talbert RL. Diabetes Mellitus. In: Dipiro JT,
Talbert RL, Yee GC, Matzke GR, Wells BG,
Posey
LM.
Pharmacotherapy,
A
Pathophysiologic Approach. 7th ed; New
York: McGraw Hill; 2008. p. 1205-1237.
2.
Norris SL, Nichols PJ, Caspersen CJ, Glasgow
RE, Engelgau MM, Jack L. et. al. The
Effectiveness
of
Disease
and
Case
Volume 03 Issue 08-2023
13
International Journal of Advance Scientific Research
(ISSN
–
2750-1396)
VOLUME
03
ISSUE
08
Pages:
9-13
SJIF
I
MPACT
FACTOR
(2021:
5.478
)
(2022:
5.636
)
(2023:
6.741
)
OCLC
–
1368736135
Management for People with Diabetes. Am J
Prev Med 2002; 22 (4S): 15-38.
3.
Jaybhaye S, Kamble R, Raju A, Bhandari A and
Sreenivas SA, “Tissue
-Polymer Compatibility
Studies of Agar Based Nimesulide Drug
Implants” Journal of Pharmacy Research.,
2012, 5(4), 2178-2180.
4.
Manohar VS, Jayshree T, Kishore KK, Rupa LM,
Dixit R, Chandrashekhar N. Evaluation of
hypoglycemic and antihyperglycemic effect of
freshly prepared aqueous extract of Moringa
oleifera leaves in normal and diabetic rabbits.
J.Chem.Pharm.Res 2012; 4(1): 249-253.
5.
Rao AV, Madhuri VR, Prasad YR. Evaluation of
the invivo hypoglycemic effect of Neem
(Azadirachta Indica A. Juss) fruit aqueous
extract in Normoglycemic rabbits. Research
Journal of Pharmaceutical, Biological and
Chemical Sciences. 2012; 3(1): 799-806.
6.
Aragao D, Guarize L, Lanini J, Da Costa J.
Hypoglycemic
effects
of
Cecropia
pachystachya in normal and alloxan-induced
diabetic rats. Journal of Ethnopharmacology
2010;128: 629-633.
7.
Etuk E. Animals models for studying diabetes
mellitus. Agric.Biol.J.N.Am 2010; 1(2): 130-
134.
8.
Alam S, Khan A, Sirhindi G, Khan S. Alloxan
Induced Diabetes In Rabbits. Pakistan Journal
of Pharmacology 2005; 22(2): 41-45.
9.
Srinivasan K and Ramarao P. Animal models
in type 2 diabetes research: An overview.
Indian J Med Res 2007; 125:451-472.
10.
Vogel H. Drug Discovery and Evaluations:
Pharmacological Assays. Antidiabetic activity.
2nd revised ed. New York: Springer; 2002.
11.
Gupta SK. Drug Screening Methods,
Antidiabetic Agents. 2nd ed. New Delhi:
Jaypee Brothers medical publishers;2009.
